Latest clinical and nursing programme

Day 1

0930
Welcome & opening remarks

Plenary - Can we tell you a story? Why we are here - an OPAT journey from the clinician and patient perspectives
0940
A challenging case - the clinical story
1000
My patient experience as an OPAT patient
1010
Q&A

Plenary Session: Debate - Oral versus IV: Implications of the OVIVA Study
1030
Argument for early switching
1045
The alternative view including resistance, patients excluded from OVIVA study, impact of the microbiome, stewardship, side effects, ddis and oral therapies
1100
Questions from the floor

1145
Refreshments and networking

Parallel session one - Improving OPAT safety: Managing patient and service risk factors
1200
What makes a patient suitable or unsuitable for OPAT? How to assess
1220
How do we measure patient compliance? How far does this impact on outcomes?
1240
Managing treatment risks - how to reduce complications and initiate robust critical incident reporting procedures
1300
The competent OPAT team: developing skills and competence
Parallel session two - Free paper session
1200
Selected from abstracts
1215
Selected from abstracts
1230
Selected from abstracts
1245
Selected from abstracts

1330
Lunch and poster viewing

Plenary sponsored symposium
1415
Cardiome

Keynote lecture
1500
OPAT and the UK Government agenda

Parallel session one - Pitching your OPAT business case to the Board: Exactly what is important?
1530
CEO view
1540
CEO view
1550
Linking to a Sustainable Transformation Plan
1610
Panel discussion with Q&A
Parallel session two - Vascular Health and Vascular Access Issues

1630
Refreshments and networking

Parallel session one - New and novel OPAT therapies and strategies
1700
Paediatrics
1720
Treating acute bacterial skin and skin structure infections?
1740
Dalbavacin & OPAT - case series
Parallel session two - Vascular Health and Vascular Access Issues … continued

1820
Welcome drinks, networking and poster presentations
Day 2

0730
Breakfast refreshments

Plenary session
0745
Plenary Session - Clinical case studies: expert panel discussion

Parallel session one - Treatments and pathways
0900
tbc
Parallel session two - Common vascular challenges
0900
tbc

Parallel session one - Respiratory disease and OPAT
1000
Cystic fibrosis
1020
Bronchiectasis
1040
Tuberculosis
Parallel session two - Workshop: Practical nursing aspects of OPAT
1000
tbc

1100
Refreshments and networking

1130
Sponsored symposium - Baxter

Plenary session - Driving the future of OPAT in the UK
1215
Drug stability
1235
Update to the Good Practice Recommendations & Introduction of Competencies
1300
Re-introduction of NORS and optimising medicine agenda
1315
Whats in store for 2018?

1335
Closing Remarks